OHRP vs. SBFM, CMRA, BDRX, GRI, PBLA, HSTO, SPRC, EVFM, EVLO, and NBSE
Should you be buying OHR Pharmaceutical stock or one of its competitors? The main competitors of OHR Pharmaceutical include Sunshine Biopharma (SBFM), Comera Life Sciences (CMRA), Biodexa Pharmaceuticals (BDRX), GRI Bio (GRI), Panbela Therapeutics (PBLA), Histogen (HSTO), SciSparc (SPRC), Evofem Biosciences (EVFM), Evelo Biosciences (EVLO), and NeuBase Therapeutics (NBSE). These companies are all part of the "medical" sector.
OHR Pharmaceutical (NASDAQ:OHRP) and Sunshine Biopharma (NASDAQ:SBFM) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, community ranking, media sentiment, dividends, institutional ownership, valuation and profitability.
OHR Pharmaceutical received 294 more outperform votes than Sunshine Biopharma when rated by MarketBeat users. However, 100.00% of users gave Sunshine Biopharma an outperform vote while only 72.13% of users gave OHR Pharmaceutical an outperform vote.
OHR Pharmaceutical has a beta of 0.84, meaning that its share price is 16% less volatile than the S&P 500. Comparatively, Sunshine Biopharma has a beta of 1.17, meaning that its share price is 17% more volatile than the S&P 500.
OHR Pharmaceutical has a net margin of 0.00% compared to Sunshine Biopharma's net margin of -18.70%. Sunshine Biopharma's return on equity of -21.03% beat OHR Pharmaceutical's return on equity.
Sunshine Biopharma has higher revenue and earnings than OHR Pharmaceutical.
Sunshine Biopharma has a consensus price target of $260.00, suggesting a potential upside of 27,856.99%. Given Sunshine Biopharma's higher possible upside, analysts plainly believe Sunshine Biopharma is more favorable than OHR Pharmaceutical.
10.7% of OHR Pharmaceutical shares are owned by institutional investors. Comparatively, 42.0% of Sunshine Biopharma shares are owned by institutional investors. 12.5% of OHR Pharmaceutical shares are owned by insiders. Comparatively, 4.1% of Sunshine Biopharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
In the previous week, Sunshine Biopharma had 3 more articles in the media than OHR Pharmaceutical. MarketBeat recorded 3 mentions for Sunshine Biopharma and 0 mentions for OHR Pharmaceutical. Sunshine Biopharma's average media sentiment score of 0.25 beat OHR Pharmaceutical's score of 0.00 indicating that Sunshine Biopharma is being referred to more favorably in the news media.
Summary
Sunshine Biopharma beats OHR Pharmaceutical on 11 of the 14 factors compared between the two stocks.
Get OHR Pharmaceutical News Delivered to You Automatically
Sign up to receive the latest news and ratings for OHRP and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding OHRP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
OHR Pharmaceutical Competitors List
Related Companies and Tools
